Diatreme Resources (ASX:DRX) is an emerging Australian producer of mineral and silica sands based in Brisbane. Our key projects comprise the Northern Silica Project and Galalar Silica Sand Project in Far North Queensland, located next to the world's biggest silica sand mine at Cape Flattery.
Copyright 2024 – Finance News Network
Source: Finance News Network
26 Aug 2021 - Chimeric Therapeutics Limited (ASX:CHM) Chief Operating Officer Jennifer Chow talks about the company's licensing of a novel, third-generation CDH17 CAR T cell therapy from the University of Pennsylvania, its recent FDA IND clearance and plans for ongoing growth.
Read More23 Dec 2019 - Cyclopharm Limited (ASX:CYC) Managing Director and CEO, James McBrayer talks about the company's joint venture to expand Positron Emission Tomography (PET) diagnostics business opportunities for NSW and Australia.
Read More27 Aug 2021 - LBT Innovations Limited (ASX:LBT) CEO and Managing Director Brent Barnes provides an update on sales and distribution for the company's Automated Plate Assessment System (APAS), which is used to read culture plates in laboratories.
Read More29 07 2024 - Bryan Quinn - CEO & Managing Director - Aurelia Metals (ASX:AMI) is an Australian mining and exploration company with a highly strategic landholding, and two operating mines in New South Wales (NSW). The Peak Mine is in the Cobar Basin in western NSW, and the Dargues Mine is in south-eastern NSW. The Hera mining operation, also located in the Cobar Basin, has ceased and the surface facilities have been placed into care and maintenance.
Read More25 Oct 2024 - Australia's semiconductor industry will be showcased in a landmark event, the inaugural Semiconductor Australia 2024 conference. The event aims to boost investment and awareness, positioning Australia as a key player in the global tech landscape.
Read More11 Dec 2020 - Cyclopharm Limited (ASX:CYC) CEO & Managing Director James McBrayer talks about USFDA approval for Technegas, the company's USA commercialisation plan, and opportunities beyond its key diagnostic market for pulmonary embolism.
Read More28 Aug 2019 - Noxopharm Limited (ASX:NOX) CEO Dr Greg van Wyk discusses the company's anti-prostate cancer drug Veyonda, its efficacy in prostate cancer treatment, the drug’s upside and the company’s strategy for growth.
Read More12 Nov 2021 - Novatti Group Limited (ASX:NOV) CEO Peter Cook talks about the company's acquiring business and recent licences with Visa and Mastercard.
Read More10 Oct 2023 - Tara French - Managing Director - Cazaly Resources (ASX:CAZ) is a Perth based Australian diversified mineral exploration and resource development company.
Read More10 Mar 2025 - CEO Marc Voigt on Clinical Trials, Regulatory Milestones, and Market Growth
Read More
